Recently, Fragoso et al. presented an observational evaluation from data of the MSBase
registry to assess correlation between lymphopenia and treatment response in a fingolimod
treated cohort of relapsing-remitting multiple sclerosis patients (
Fragoso et al., 2017
). Based on its unique mechanism of action as sphingosin-1-phosphate receptor agonist,
fingolimod usually leads to a rapid and intense decrease of peripheral lymphocyte
subsets in treated patients (
- Fragoso Y.D.
- Spelman T.
- Boz C.
- Alroughani R.
- Lugaresi A.
- Vucic S.
- Butzkueven H.
- Terzi M.
- Havrdova E.
- Horakova D.
- Granella F.
- Olascoaga J.
- Sánchez-Menoyo J.L.
- Pucci E.
- Barnett M.
- Brooks J.B.B.
- Haartsen J.
Lymphopenia and efficacy of fingolimod msbase sub-study investigators. Lymphocyte
count in peripheral blood is not associated with the level of clinical response to
treatment with fingolimod.
Mult. Scler. Relat. Disord. 2017; 19 (Nov 22): 105-108
Thomas et al., 2017
). Although already approved in 2010, the association of distinct T cell subset distribution
and clinical disease activity is still part of debate (
Song et al., 2015
;
Paolicelli et al., 2017
;
Teniente-Serra et al., 2016
). In their current report, Fragoso et al. picked up this issue and compared two propensity
matched groups of multiple sclerosis patients that presented lymphocyte levels <750/mm3 versus lymphocyte levels never < 1000/mm3 during fingolimod treatment. Interestingly, Fragoso and colleagues could not define
significant differences in clinical response between both chosen treatment groups
and conclude, that peripheral blood lymphocyte count is not associated with clinical
disease activity reflected by relapses or EDSS progression in fingolimod treated patients.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.Mult. Scler. 2017; 23: 1479-1487
- Lymphopenia and efficacy of fingolimod msbase sub-study investigators. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.Mult. Scler. Relat. Disord. 2017; 19 (Nov 22): 105-108
- Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings.Mult. Scler. Relat. Disord. 2014; 3: 494-504
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. FREEDOMS Study Group.N. Engl. J. Med. 2010; 362 (Feb 4): 387-401
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.Neurology. 2011; 76: S20-S27
- Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.J. Neuroimmunol. 2017; 303 (Feb 15): 75-80
- Real world effectiveness of first-line use of Gilenya: a two-site retrospective study.AAN. 2017; (Poster Nr. 361)
- Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.PLoS One. 2015; 10 (Apr 28): e0124923
- Baseline differences in minor lymphocyte subpopulations may predict response to fingolimod in relapsing-remitting multiple sclerosis patients.CNS Neurosci. Ther. 2016; 22: 584-592
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Expert Opin. Pharmacother. 2017; 18: 1649-1660
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.Neurology. 2014; 83 (Dec 2): 2153-2157
Article info
Publication history
Published online: March 22, 2018
Accepted:
March 15,
2018
Received:
December 7,
2017
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
